Bentley Pharmaceuticals, Inc. (NYSE: BNT), a specialtypharmaceutical and drug delivery company, announced today that FredFeldman, Ph.D., Vice President of Research and Development and RobertStote, MD, FACP, Chief Medical Officer, will present at the CIBCAnnual Biotechnology & Specialty Pharmaceuticals Conference takingplace at the Millennium Broadway Hotel in New York City. Bentley'spresentation of "New Drug Delivery Potentials for Treatment ofDiabetes" is scheduled for Tuesday, April 4, 2006 at 3:15 p.m.(Eastern Standard Time).
Bentley Pharmaceuticals, Inc. is a specialty pharmaceuticalcompany focused on advanced drug delivery technologies andpharmaceutical products. Bentley's proprietary drug technologiesenhance or facilitate the absorption of pharmaceutical compoundsacross various membranes. Bentley also manufactures a growingportfolio of generic and branded pharmaceuticals in Europe for thetreatment of cardiovascular, gastrointestinal, infectious andneurological diseases through its subsidiary, Laboratorios Belmac, andmarkets these pharmaceutical products through its subsidiaries,Laboratorios Belmac, Laboratorios Davur, Laboratorios Rimafar andBentley Pharmaceuticals Ireland; and manufactures and markets activepharmaceutical ingredients through its subsidiary, Bentley API.
Copies of Bentley Pharmaceuticals' press releases and otherinformation may be obtained through Bentley's web site atwww.bentleypharm.com.
